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HER-2/neu is a tumour antigen that is overexpressed in human breast tumours. Among the vaccine strategies developed to
overcome immune tolerance to self-proteins, vaccination with anti-idiotypic (anti-Id) antibodies has been described as a promising
approach for treatment of several malignant diseases. To develop an active immunotherapy for cancer patients positive for HER-2/
neu, we investigated immunisation with human anti-Id single-chain fragments (scFv) mimicking the conformation of HER-2/neu
protein to induce a humoral response in mice. We selected by phage display two human anti-Id scFv (Ab2b) directed against
trastuzumab F(ab0)2 fragments (Ab1), a humanised anti-HER-2/neu monoclonal antibody. Using competitive ELISA and Biacore
biosensor analysis, we showed that anti-Id scFv 40 and scFv 69 could inhibit HER-2/neu binding to trastuzumab. Following vaccination
of BALB/c mice with the soluble or phage-displayed scFv, Ab3 polyclonal antibodies, and among them Ab10 antibodies able to bind
HER-2/neu, were detected in the sera of the immunised mice. These results demonstrate that the human anti-Id scFv could act as a
surrogate antigen for HER-2/neu. The present study strongly suggests that the novel 30kDa human mini-antibody could be used as an
anti-idiotype-based vaccine formulation to induce an effective humoral response in patients bearing HER-2/neu-positive tumours.
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For active cancer immunotherapy, the tumour-associated antigen
(TAA) HER-2/neu is a promising cancer vaccine candidate since it
is overexpressed on the surface of a number of human cancers, but
its expression in normal tissue is restricted. This 185-kDa
transmembrane phosphoglycoprotein consists of a cysteine-rich
extracellular domain (ECD) that functions in ligand binding and
an intracellular cytoplasmic domain with kinase activity. More-
over, HER-2/neu is a member of the epidermal growth factor
receptor family (Coussens et al, 1985; Bargmann et al, 1986).
Cancers in which HER-2/neu protein overexpression occurs
include human adenocarcinomas such as breast (in 20–40% of
intraductal carcinomas) (Slamon et al, 1987) or ovary (in 30%)
(Berchuck et al, 1990). Although overexpression has been linked to
more aggressive disease and a poorer prognosis in node-positive
breast cancer, it has also been established that it is related to a
favourable prognosis in some patients with stage I breast tumours
that contain inflammatory infiltrates which may represent an
immune response directed against autologous cancer cells (Rilke
et al, 1991). One hypothesis is that the better outcome in these
patients may be related to the generation of an HER-2/neu-specific
immune response which could directly or indirectly limit further
growth and metastasis. Different investigations defining HER-2/
neu-specific immunity in patients with cancer indicate that high
levels of both T cell and antibody immunity exists in some
patients, even if it is low or lacking in the majority of them
(Disis et al, 1994; Fisk et al, 1995; Peoples et al, 1995). This
strongly suggests that immunological tolerance exists, probably
related to the oncofetal origin of HER-2/neu, and that it represents
a barrier to effective vaccination against this antigen (Nanda and
Sercarz, 1995; Disis et al, 1998). Furthermore, different studies
have proven that anti-HER-2/neu monoclonal antibodies
(mAbs) can be effective in eradicating tumours (Baselga and
Albanell, 2001).
These findings have stimulated further studies to test vaccine
strategies to induce and increase immunity to HER-2/neu for the
treatment of breast cancer or for the prevention of recurrent
disease. Effective vaccine strategies must circumvent tolerance. For
this reason, methods to break this tolerance, such as presenting the
critical epitope in a different molecular environment to the
tolerised host, have been developed. Several studies have evaluated
whether tolerance to HER-2/neu could be circumvented by
immunisation with either peptide-based vaccines (Disis et al,
1996, 2002; Dakappagari et al, 2000) or DNA (Concetti et al, 1996;
Di Carlo et al, 2001; Pilon et al, 2001). Some encouraging results
were obtained but with persistence of problems such as the weak
immunogenicity of the peptides or the potential adverse effect of
administering plasmid DNA encoding a functional oncogene. In
this context, the immune network hypothesis (Jerne, 1974) seems
to offer a unique approach to transform epitope structures into Id
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sdeterminants expressed on the surface of antibodies. Active
immunisation with tumour-specific Id vaccines has very early
been shown to inhibit tumour growth in animals (Kennedy et al,
1985). Carcinoembryonic antigen (CEA) mimicry by (i) an anti-Id
single-chain variable fragment (scFv) constructed from a murine
mAb (Tripathi et al, 1998) and (ii) murine dendritic cells pulsed
with anti-Id antibody (Saha et al, 2003) were published with
convincing results regarding the level of the humoral response
raised in mice. Recently, a study from the same group also
described the use of a murine monoclonal anti-Id antibody as a
surrogate antigen for human HER-2/neu (Baral et al, 2001). In
human trials, if the experience using anti-Id antibodies to
stimulate immunity against tumours is limited, the results are
promising with minimal observed toxicity. Anti-Id antibodies that
functionally mimic an antigen have been used for the treatment of
colorectal carcinoma (CEA, (Foon et al, 1999)), B-and T-cell
lymphoma (gp72 (Kwak et al, 1992), and gp37 (Bhattacharya-
Chatterjee et al, 1988), respectively), and for the treatment of
melanoma by triggering an active immune response against the
disialoganglioside GD2 (Foon et al, 2000). Anti-Id mAbs mimick-
ing the human high molecular weight melanoma-associated
antigen have been tested in a clinical trial to implement active
specific immunotherapy (Mittelman et al, 1990).
Antibody-variable region fragments, obtained by recombinant
DNA technology among which phage display methodology
(Winter et al, 1994), have attracted considerable attention, since
these products can be easily engineered for specific purposes such
as therapy of cancer (Nilsson et al (2000) for a review).
Using the synthetic human ETH-2 library (Pini et al, 1998), we
selected by phage display and characterised anti-Id scFv (Ab2)
directed against the trastuzumab F(ab0)2 fragments (Ab1). Data
obtained from an in vivo study using different immunisation
schedules indicate that these human anti-Id scFv can induce an
effective anti-HER-2/neu humoral response in experimental
animals and suggest that they could serve as a surrogate for the
tumour antigen HER-2/neu.
MATERIALS AND METHODS
Materials
The human ovarian SK-OV-3 cell line, which overexpresses HER-
2/neu, and the hamster ovarian CHO cell line were obtained from
American Type Culture Collection (Rockville, MD, USA). All the in
vivo experiments were performed in compliance with the French
guidelines for experimental animal studies (Agreement No.
A34220) and fulfil the UKCCCR Guidelines for the welfare of
animals in experimental research. Six-to eight-week-old female
BALB/c mice were obtained from Iffa Credo (L’arbresle, France).
The ETH-2 synthetic human antibody phage library in the scFv
format (Pini et al, 1998) was kindly provided by Dr D Neri (ETH
Zurich, Switzerland). Anti-HER-2/neu monoclonal antibody FRP5
was kindly provided by Professor N Hynes (FMI, Basel, Switzer-
land). Trastuzumab was purchased from Roche (F Hoffmann-La
Roche Ltd, Bazel, Switzerland). The human IgG1, used as a control,
was kindly provided by Mabge `ne (Ale `s, France). HER-2/neu ECD-
Fc fusion protein, composed of two extracellular domains of the
receptor linked by a human Fc fragment, was kindly provided by
Professor JP Mach (Biochemistry Institute, University of Lausanne,
Switzerland). Human IgG1 control and trastuzumab F(ab0)2
fragments were obtained by pepsin digestion (Sigma, St Louis,
MO, USA), at 371C for 4h, at a 3% (ww
 1) ratio of pepsin/IgG in
appropriate buffer (0.2 M sodium acetate, pH 4). The antibody
fragments were purified by gel-filtration chromatography on a
Sephacryl 100 column (Amersham Biosciences, Buckinghamshire,
UK). SDS–PAGE (8.5%) revealed more than 95% purity of the
deposited proteins.
Phage display selection of anti-trastuzumab F(ab0)2
fragments anti-Id scFv antibodies (Ab2)
Protocols for phage display panning, and analysis were as
previously described (Pini et al, 1998). The phage-displayed
library was panned with trastuzumab F(ab0)2 fragments in three
sequential rounds of panning on immunotubes. Briefly, 5 10
12
phages were added to tubes, coated with trastuzumab F(ab0)2
fragments at a concentration of, respectively, 100, 50 and
10mgml
 1 in PBS for all three rounds. Phage pools were assessed
by ELISA. In all, 96-well microtitre plates were coated overnight at
41C with 0.5mg protein per well with either trastuzumab or human
IgG1 F(ab0)2 fragments or anti-fd phage Ig (Sigma) in PBS. Plates
were then blocked for 2h at 371C with PBS, 2% non fat-dried milk.
A volume of 100ml of serial dilutions of polyclonal phage solutions
in PBS was added to each well. Plates were incubated at room
temperature for 1.5h. Bound phage-scFv were detected by reaction
for 1h 30min at 371C with a horseradish peroxidase (HRP)-
conjugated anti-M13mAb (Amersham Biosciences). The plates
were developed using o-phenylenediamine substrate (OPD)
according to the supplier’s instructions (Sigma).
Production and purification of anti-trastuzumab F(ab0)2
fragments soluble anti-Id scFv
After the third round of selection, Escherichia coli HB2151 cells
were infected with the phages to produce soluble antibodies rather
than phage-bound antibodies. Single ampicillin-resistant infected
E. coli HB2151 colonies were picked in 96-well tissue culture plates
and grown for 3h at 371Ci n2 TY, 100mgml
 1 ampicillin, 0.1%
glucose. ScFv expression was induced with isopropyl b-D-
thiogalactopyranoside (IPTG) to a final concentration of 1mM
for 16h at 301C. The bacterial supernatants were evaluated for
reactivity with trastuzumab or human IgG1 F(ab0)2 fragments by
ELISA. The ELISA was performed as described above except that
after incubation of E. coli HB2151 supernatants, bound soluble
scFv was detected using HRP-conjugated anti-FLAG-tag M2 Ab
(Sigma) for 1.5h.
For Western blot analysis, protein extracts were size fractionated
by SDS–PAGE (12.5%) and electroblotted onto nitrocellulose. The
blot was blocked at room temperature with shaking for 1h in TBS,
1% nonfat-dried milk, and probed at room temperature for 2h
with the detecting Ab (HRP-conjugated anti-FLAG-tag M2) in TBS,
5% skimmed dried milk. The blot was washed three times and
developed using 4-chloro-1-naphthol as substrate (Sigma).
For each positive clone, 15mg of plasmid DNA was purified
using the NucleoSpin
s Plasmid kit (Macherey-Nagel, Du ¨ren,
Germany). Sequencing reactions were carried out using the Dye
Terminator Sequencing kit for automatic determination of
sequences with ABI PRISM 377 (Applied Biosystems, Foster City,
CA, USA). The primers 50-TACTACGCAGACTCCGTGAAG-30 and
50-GAATTTTCTGTATGAGG-30 were used for annealing.
For high-scale bacterial expression and purification of scFv 39,
40 and 69, overnight cultures of E. coli HB2151 single colonies were
grown in 1l 2 TY, 100mgml
 1 ampicillin, 0.1% glucose, at 371C.
The expression of the scFv was induced for 16h at 301C by adding
1m M IPTG at 0.6 OD600 cultures. Bacterial pellets were resus-
pended in lysis buffer (30mM Tris-HCl, 20% sucrose, 1mM EDTA,
1% PMSF, pH 7) and cooled on ice for 30min. After centrifugation,
the supernatant (periplasmic fraction) was filtered through a 0.45-
mm filter. Clear supernatant from each culture was purified using
IMAC (Casey et al, 1995). ScFv were loaded onto a 5-ml Hitrap Ni-
activated Chelating HP column (Amersham Biosciences) in
loading buffer (0.02 M sodium phosphate, 0.5 M NaCl, pH 7.4)
and were eluted by applying a 25ml 0–0.5 M imidazole gradient.
ScFv-containing fractions were pooled and concentrated to a
volume o1ml on Amicon Ultra 30000 MWCO (Millipore,
Bedford, MA, USA). Additional purification was achieved by fast
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sprotein liquid chromatography on a Superdex 75 gel-filtration
column (Amersham Biosciences). The purity of the recombinant
proteins, rescued in PBS, was evaluated on SDS–PAGE (12.5%).
Protein bands were detected by silver staining.
In vitro characterisation of anti-Id scFv by ELISA and
BIACORE
To characterise the anti-Id scFv, competitive ELISA experiments
were carried out using either HER-2/neu ECD-Fc fusion protein to
inhibit the binding of soluble scFv to trastuzumab F(ab0)2
fragments (Ab1) or purified scFv to block the binding of HER-2/
neu ECD-Fc fusion protein to Ab1. Each soluble scFv was used at a
dilution giving an A490 of 1–1.5 in ELISA. An irrelevant soluble
scFv, named T1, isolated from the ETH-2 library and which does
not bind to trastuzumab F(ab0)2 fragments, was used as a control
(data not shown). In the first format, serial dilutions of HER-2/neu
ECD-Fc fusion protein, ranging in concentration from 25 to
0mgml
 1, were used as inhibitor solutions; bound soluble scFv was
detected as previously described. Recombinant human carcinoem-
bryonic antigen (rhCEA) was used as an irrelevant inhibitor. This
format of inhibition was also used immediately after the third
round of selection to check the inhibition of the binding of
individual periplasmic fractions on trastuzumab F(ab0)2 fragments
by HER-2/neu ECD-Fc fusion protein. In the second format,
competition was performed using various concentrations of
purified soluble scFv ranging from 250 to 0mgml
 1 solutions
and HER-2/neu ECD-Fc fusion protein at a dilution giving an A490
of 1–1.5 in ELISA. Bound HER-2/neu ECD-Fc fusion protein was
subsequently detected with HRP-conjugated anti-HER-2/neu
FRP5mAb.
Binding experiments of anti-trastuzumab F(ab0)2 fragments scFv
and HER-2/neu ECD-Fc fusion protein on trastuzumab F(ab0)2
fragments were performed at 251C by SPR analysis using a
BIACORE 2000 instrument (Biacore AB, Uppsala, Sweden).
Trastuzumab F(ab0)2 fragments were covalently immobilised on a
CM5 sensor chip surface using the amine coupling method
according to the manufacturer’s instructions (Biacore AB). A
control reference surface was prepared using the same chemical
treatment of the flow cell surface without injection of trastuzumab
F(ab0)2 fragments. HER-2/neu ECD-Fc fusion protein (15mgml
 1)
and soluble scFv (50mgml
 1) in HBS-EP buffer (10mM HEPES,
3m M EDTA, 150mM NaCl, 0.005% P20, pH 7.4) were injected over
the flow cell and the dissociation phase was followed by a
regeneration step (10ml 100mM HCl). The flow rate was
50mlmin
 1. All the sensorgrams were corrected by subtracting
the low signal of the control reference surface. The BIA evaluation
3.2 software was used to fit the data using a 1:1 Langmuir global
model. For the inhibition experiments, a first injection of anti-Id
scFv 69 (50mla t2mM) was followed by a second injection of HER-
2/neu ECD-Fc fusion protein (50ml at 0.06mM). After a regenera-
tion step with 10ml of 100mM HCl, a similar experiment was
performed with a first injection of buffer instead of the scFv. The
flow rate was 10mlmin
 1. To evaluate the percent inhibition, we
injected the anti-Id scFv 69 followed by a long dissociation step.
This dissociation curve was then substracted from the HER-2/neu
association curve.
Analysis of the Ab3 response in mouse sera
Two immunisation schedules were carried out. In the first one
(protocol 1), five 6- to 8-week-old female BALB/c mice per group
were immunised i.p. monthly for 3 months with 50mg of either
purified soluble anti-Id scFv 40 or 69, 20mg of HER-2/neu ECD-Fc
fusion protein in 100ml PBS (negative control group). Injections
were performed after emulsion with CFA for the first immunisa-
tion and with IFA for subsequent ones. In the second protocol,
inspired by the work of Magliani et al (1998), 6-to 8-week-old
female BALB/c mice were immunised four times. A first s.c.
injection of either 50ml of freshly prepared phage-scFv 40 or 69 at a
titre of 10
14TUml
 1,2 0mg of HER-2/neu ECD-Fc fusion protein,
or PBS was performed after emulsion with CFA. This injection was
followed 2 weeks later by a second s.c. administration of the same
dose with IFA. Two additional injections were given i.p. at 21 and
35 days after the initial immunisation (protocol 2). For serum
antibody measurement, mice were bled and sera were drawn from
the tail vein and stored at  201C for assay. The sera were checked
for anti-anti-Id (Ab3) responses by flow cytometry and ELISA on
the HER-2/neu ECD-Fc fusion antigen as described below. Analysis
of the results obtained was also performed according to the
method described by Magliani et al (1998). A positive control
consisting of pooled sera from mice immunised with HER-2/neu
ECD-Fc fusion protein was included in each determination. Results
were expressed in arbitrary units as the ratio between absorbance
of the test serum to 70% of the absorbance of the positive control
serum multiplied by 1000. The 30%, subtracted from the positive
control serum absorbance, was due to the anti-Fc response (see
Results).
To detect anti-anti-Id scFv in mouse sera, an ELISA was
performed by coating 96-well plates with soluble anti-Id scFv at
5mgml
 1 and then washing and blocking with PBS, 1% BSA for 2h
at 371C. Serial dilutions of sera from immunised mice (1 to 1:3200
in PBS, 0.5% BSA) were incubated for 1.5h at room temperature.
Bound IgG was detected after incubation for 1.5h of a HRP-
conjugated goat anti-mouse IgG (Sigma).
To further confirm the presence of anti-anti-Id scFv, an
inhibition ELISA was performed by preincubating serial dilutions
of sera from immunised mice (1 to 1:640 in PBS, 0.5% BSA) with
soluble scFv for 2h at 371C. Next, 100ml of each mixture was added
to the wells, coated with soluble anti-Id scFv. The plates were
incubated at room temperature for 1.5h. Bound scFv were detected
as previously described.
ELISA and FACS analysis of anti-HER-2/neu antibodies
(Ab10) in mouse sera
Indirect ELISA was performed by coating 96-well plates overnight
at 41C with HER-2/neu ECD-Fc fusion protein at 2mgml
 1 and
then blocked with PBS, 1% BSA. A volume of 100ml of diluted sera
from mice (1:100 in PBS, 0.5% BSA) were added in each well and
incubated for 1.5h at room temperature. Then, 100ml of either goat
anti-mouse IgG (whole molecule)-HRP conjugate, goat anti-mouse
IgG (g-chain specific)-HRP conjugate, or goat anti-mouse IgM (m-
chain specific)-HRP conjugate was added, incubated for 1.5h, and
detected as described above.
For FACS analysis, HER-2/neu-positive SK-OV-3 and HER-2/
neu-negative CHO cell lines were incubated for 1h at 41C with
either 100ml of each mouse serum or 100ml trastuzumab diluted in
PBS, 1% BSA, 1mgml
 1 azide. After washing, the cells were
incubated for another 45min at 41C with either 100ml of diluted
sheep anti-mouse IgG-FITC-labelled antibody for sera or anti-
human-FITC-labelled antibody (Sigma) for trastuzumab. The
stained cells were suspended in 500ml PBS, and stored at 41C
before FACScan analysis (Becton Dickinson, Franklin Lakes, MD,
USA).
RESULTS
Isolation of an anti-Id scFv
The selection of the anti-Id scFv, performed by three rounds of
panning of the synthetic ETH-2 scFv library on immobilised
trastuzumab F(ab0)2 fragments (Ab1), resulted in a substantial
affinity enrichment of the library on either trastuzumab or human
IgG1 F(ab0)2 fragments (used as a control) as checked by ELISA
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susing the recombinant polyclonal phage supernatants. A 2 10
4-
fold increase of phage titre between the first and the third round of
selection was also observed. After cloning, antibody supernatants
derived from 96 induced individual clones of the third round were
then used to infect E. coli HB2151 to produce soluble scFv
antibodies. In total, 96 periplasmic fractions were tested for their
reactivity with human IgG1 or trastuzumab F(ab0)2 fragments by
ELISA. The ratio between the number of phages specific for
trastuzumab and those reacting with irrelevant (Fab0)2 IgG was
about 30% after the third round of selection. Western blot analysis
of the positive periplasmic fractions led us to select scFv antibodies
consisting of single monomers with the approximate molecular
mass of about 30kDa and to exclude those with a lower molecular
mass (Figure 1A). The selected periplasmic fractions were checked
by ELISA for inhibition of their binding on trastuzumab F(ab0)2
fragments by either HER-2/neu ECD-Fc fusion protein or rhCEA
(recombinant human CEA used as an irrelevant inhibitor). Only
clones showing marked inhibition (450%) were further analysed.
After DNA sequence determination of the VH and VL regions of the
antibodies, three unique scFv were selected (Table 1). The three
antibodies exhibited different random loops introduced at position
95 of VH or VL and used germline gene segments corresponding to
DP-47 for the heavy chain and DPL-16 for the light chain.
Anti-Id scFv 39, 40 and 69 were purified to 90% homogeneity
using immobilised metal ion affinity chromatography (IMAC)
followed by gel filtration on a Superdex 75 as shown in Figure 1B
for anti-Id scFv 69. Anti-Id scFv 39 and 40 were obtained with the
same level of purity. These three scFv were also expressed,
displayed on phage after infection of E. coli TG1, and the
immunoreactivity of each phage solution controlled by ELISA on
trastuzumab F(ab0)2 fragments (data not shown).
In vitro characterisation of the Ab2 anti-Id scFv
To characterise the binding properties of the anti-Id scFv, we first
checked whether or not these scFv exhibited competitive binding
with trastuzumab F(ab0)2 fragments (Ab1) for HER-2/neu epitopes.
When the HER-2/neu ECD-Fc fusion protein was used as an
inhibitor, the binding of both anti-Id scFv 40 and 69 on
trastuzumab F(ab0)2 fragments was inhibited by approximately
90% (Figure 2A). The binding of anti-Id scFv 39 was only inhibited
by 23%; thus, anti-Id scFv 39 was not used for subsequent
experiments. The same competition experiment was performed
using rhCEA (185kDa) (Figure 2B). Inhibition curves showed that
even at high concentrations of rhCEA, this antigen (whose
molecular mass is nearly the same as the HER-2/neu ECD-Fc
fusion protein) was unable to compete with anti-Id scFv for the
binding on trastuzumab F(ab0)2 fragments. Anti-Id scFv 40 and 69
were subsequently used to inhibit the binding of HER-2/neu
A
B
scFv
a b c d kDa
4 3 2 1
30 kDa
66
55
36
31
21
14
Figure 1 Analysis of antibody-containing periplasmic fractions containing
antibodies (A) After induction of single ampicillin-resistant infected E. coli
HB2151 colonies with 1mM IPTG. Lane 1: clone 39; lane 2: clone 40; lane 3:
clone 92; lane 4: clone 69. After size fractionation on 12.5% SDS–PAGE,
protein extracts were blotted onto nitrocellulose. The immunoblot was
developed with HRP-conjugated M2 anti-FLAG mAb (1:2000) followed
by addition of the 4-chloro-1-naphtol substrate. (B) Before and after
purification. The purity was controlled on 12.5% SDS–PAGE gel followed
by silver staining. Lane a: nonpurified periplasmic fraction. Lane b:
Periplasmic fraction purified on a Hitrap Ni-activated chelating column.
Lane c: Periplasmic fraction purified on a Hitrap Ni-activated chelating
column followed by gel filtration on Superdex 75. Lane d: Standard
molecular mass markers.
Table 1 Predicted amino-acid sequences of the CDR3 regions of VH and
VL domains of the three unique scFv 39, 40 and 69
a
scFv H-CDR3 L-CDR3
39 CAKKKIGPFDY NSSNSSPRPNAPVVF
40 CAKNYQIHPFDY NSSDPDQLLVVF
69 CAKNVHIQPFDY NSSEPTPPRVVF
aAmino-acid sequences are given in the one letter code. Random loops of 5 or 6
amino acids introduced at position 95 of VH or VL are in bold characters.
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Figure 2 Inhibition of purified soluble scFv 39, 40 and 69 binding on
trastuzumab F(ab0)2 fragments by (A) HER-2/neu ECD-Fc fusion protein
and (B) rhCEA, using a competitive ELISA. Increasing amounts of inhibitor
were mixed with either anti-Id scFv 39, 40 or 69 used at a dilution giving an
A490 ranging from 1 to 1.5 in ELISA (corresponding to a concentration of
about 20mgml
 1). The incubation on trastuzumab F(ab0)2 fragments for
1.5h was followed by the detection of scFv binding with HRP-conjugated
M2 anti-FLAG mAb (1:2000). The results obtained are expressed as
percent inhibition at each concentration of inhibitor.
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sECD-Fc fusion protein at two different concentrations on
trastuzumab F(ab0)2 fragments. In this format, the maximum
inhibition observed was nearly 40% for anti-Id scFv 69 at
30mgml
 1 (Figure 3) and even with concentrations up to
250mgml
 1 (data not shown). The same result was obtained for
anti-Id scFv 40 (data not shown).
Binding kinetic parameters of anti-Id scFv 40 and 69 on
immobilised trastuzumab F(ab0)2 fragments were measured using
surface plasmon resonance (SPR) technology (Figure 4A). Whereas
the affinity constants of both scFv were in the same order of
magnitude (5mM), anti-Id scFv 40 showed higher association and
dissociation rates than those of scFv 69 (Figure 4A). Under the
same conditions, the affinity constant of HER-2/neu ECD-Fc fusion
protein was in the nanomolar range (KD¼2.970.1nM). The
inhibition of the binding of HER-2/neu ECD-Fc fusion protein on
immobilised trastuzumab F(ab0)2 fragments by anti-Id scFv 69 was
also evaluated using this technology. The prior injection of anti-Id
scFv 69 inhibited by 83% the binding of HER-2/neu ECD-Fc fusion
protein on trastuzumab F(ab0)2 fragments (Figure 4B). These
results confirmed the data obtained by competitive ELISA and
gave an even higher percent inhibition, suggesting that anti-Id
scFv 40 and 69 could be true Ab2b. If so, these scFv should be able
to induce a polyclonal anti-anti-Id response (Ab10) when injected
into mice.
Immunising properties of anti-Id scFv 40 and anti-Id
scFv 69
Six-to eight-week-old female BALB/c mice were immunised either
i.p. with soluble purified anti-Id scFv 40 and 69 (protocol 1) or s.c.
with scFv displayed on phages (protocol 2). Sera of the five mice in
each group were individually tested by ELISA for their reactivity
against Ab2 immunogens (anti-Id scFv 40 or 69) after three or four
injections. All the mice developed significant immunity against
anti-Id, and the titres were further increased with further
immunisations in both protocols (see Sect. 2.4). Preimmune sera
or control sera of mice immunised with PBS were tested negative
against anti-Id scFv 40 and anti-Id scFv 69. No specific response
was observed either in sera of mice injected with wild-type phages
(data not shown). To demonstrate the specificity of the Ab3
response against anti-Id scFv, an inhibition ELISA was carried out
by inhibiting the binding of each anti-Id scFv on trastuzumab
F(ab0)2 fragments by serial dilutions of sera from immunised mice.
A 1:20 dilution of immune serum from a mouse immunised with
anti-Id scFv 69 displayed on phage particles inhibited by nearly
100% Ab2 (anti-Id scFv 69) binding to Ab1 (trastuzumab F(ab0)2
fragments), suggesting that antibodies contained in the sera were
true anti-anti-Id in nature (Figure 5). Anti-Id scFv 40 gave similar
results (data not shown). In contrast, no inhibition was observed
with immune sera from mice immunised with HER-2/neu ECD-Fc
fusion protein or PBS.
Idiotype analysis of Ab3 (Ab10) induced by immunisation
with anti-Id scFv
To detect the subset of antibodies called Ab10, able to bind to the
target antigen, ELISA were performed on HER-2/neu ECD-Fc
fusion protein using mouse sera diluted 1:100. The use of different
HRP-conjugated Ig allowed us to determine the IgG, IgM, and total
Ig levels induced in mouse sera by immunisation with anti-Id scFv
and control immunogens (Figure 6). The absorbance values
plotted at each time correspond to the mean value for each group
of five mice7standard deviations (s.d.). These results demon-
strated that (i) patterns of induction of IgG or IgM anti-HER-2/neu
antibodies were similar for the two immunisation protocols
(Figure 6A, B); (ii) a significant portion of the polyclonal Ab3
reacted with the antigen (Figure 6A, B), the level of Ab10 reaching a
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Figure 3 Inhibition of HER-2/neu ECD-Fc fusion protein binding on
trastuzumab F(ab0)2 fragments by purified scFv 69 by competitive ELISA.
Increasing amounts of inhibitor were mixed with HER-2/neu ECD-Fc fusion
protein at 2.5 or 5mgml
 1 and incubated with trastuzumab F(ab0)2
fragments for 1.5h. HER-2/neu ECD-Fc fusion protein binding was then
detected with peroxidase-conjugated anti-HER-2/neu FRP5mAb (1:3000).
The results obtained are expressed as percent inhibition at each
concentration of inhibitor.
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Figure 4 BIACORE experiments: (A) binding kinetics of anti-Id scFv 40,
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CM5 sensor chip and equilibrium affinity constants (inserted Table), (B)
inhibition of HER-2/neu ECD-Fc fusion protein binding on trastuzumab
F(ab0)2 fragments immobilised on a CM5 sensorchip by anti-Id scFv 69.
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shown in Figure 6C, the titres of IgM as well as IgG anti-HER-2/neu
ECD-Fc fusion protein response were, as expected, very high in the
sera of mice immunised with HER-2/neu ECD-Fc fusion protein,
whereas there was no reactivity in the negative control. In the sera
of mice immunised with HER-2/neu ECD-Fc fusion protein, part of
the very high titre against the adsorbed protein was due to an
anti-human Fc response as shown when the reactivity of these
sera against another recombinant Fc fusion protein, the
so-called MICA-Fc, (kindly provided by Dr W Held, LICR,
Lausanne Branch) was checked by ELISA. The data obtained
(not shown) led us to conclude that the anti-Fc response was about
30% of the total response observed by ELISA on HER-2/neu ECD-
Fc fusion protein.
Flow cytometric analysis of Ab10
To further confirm the nature of the Ab10 induced by injections
with anti-Id scFv 40 and 69, flow cytometric analyses of HER-2/
neu-positive SK-OV-3 cells and HER-2/neu-negative CHO cells
were performed with sera (1:100 dilution) from immunised BALB/
c mice. Using trastuzumab mAb, both HER-2/neu overexpression
at the surface of SK-OV-3 cells and the lack of expression of the
receptor on the CHO cells surface were first confirmed (Figure 7A,
B). Then, we demonstrated that antibodies not only in sera
from mice immunised with HER-2/neu ECD-Fc fusion protein
but also in sera from mice immunised either with anti-Id scFv
40 or anti-Id scFv 69, specifically stained the SK-OV-3 cells.
Only a weak reactivity was observed on CHO cell line.
Representative results obtained at the end of the two immunisation
schedules are presented also in Figure 7A, B. The fluorescence
intensity increase on SK-OV-3 cells, as compared with CHO
cells, were about 100, 25 and 2 for sera from mice immunised
with HER-2/neu ECD-Fc fusion protein, anti-Id scFv 40 or 69 and
PBS, respectively. The staining of cells obtained by using sera
from mice injected with PBS was equivalent to that of preimmune
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fragments followed by the detection of bound scFv by HRP-conjugated M2
anti-FLAG mAb. The results obtained are expressed as percent inhibition at
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Figure 6 Analysis of the Ab10 response in sera of mice. Determination of anti-HER-2/neu IgG or IgM or total Ig levels in sera collected at various times
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ssera, thus corresponding to the background signal. On the
basis of these experiments, we concluded that true Ab10 antibodies,
which are specifically directed against the HER-2/neu receptor,
were present in the sera of mice immunised with anti-Id scFv
40 and 69.
DISCUSSION
The HER-2/neu oncogenic protein is a well-characterised
TAA (Shepard et al, 1991). The main problem when using the
HER-2/neu oncoprotein as a target antigen for active immu-
notherapy is immune tolerance to this self-antigen. Ab1 therapy as
well as peptide or protein-based vaccines have been reported
(Pegram et al, 1998; Disis et al, 2002). All the studies have pointed
out the necessity to pursue the search for effective therapeutic
approaches.
The present study was conducted to further explore the
efficacy of the anti-Id (Ab2) strategy to generate an anti-HER-2/
neu immune response. Trastuzumab, a humanised mAb
specific for HER-2/neu, whose efficiency has been proven
both alone and in combination with various chemotherapeutic
agents in women with HER-2-positive metastatic breast cancer
(Cobleigh et al, 1999; Slamon et al, 2001), was chosen as Ab1.
Several authors have pointed out that a distortion of the scFv
derived from a monoclonal anti-Id antibody or the differential
orientation of the VH or VL domain in a scFv construct are likely to
affect its antigen mimicry (Francisco et al, 1995; Tripathi et al,
1998). For this reason, the phage display technology was chosen to
isolate human anti-Id scFv fragments from the synthetic ETH-2
library (Pini et al, 1998) since (i) such scFv do not need further
engineering and (ii) they could be used for repeated immunisa-
tions of cancer patients without invoking a human anti-mouse
antibody response.
The affinity selection was performed using proteolytically
cleaved F(ab0)2 fragments of trastuzumab to avoid the selection
of scFv specific for the Fc portion of the human IgG1. By using a
conventional selection and elution method, we obtained specific
clones with a diversity of 15%. Such a diversity, which is expected
using this technique, could probably be improved by the
method recently described by Goletz et al (2002), which involves
specific elution with the antigen followed by trypsin treatment of
eluted phages for generating large diversities of anti-Id single-
chain antibody fragments from nonimmunised phagemid libraries
using phage display. In our study, after the three rounds of
panning, the selection procedure was based first on the direct
binding of periplasmic fractions from individual E. coli HB2151
colonies to trastuzumab, their failure to bind to control IgG1, and
secondly on a competitive ELISA using the antigen as inhibitor.
Only clones whose binding to trastuzumab was markedly inhibited
by soluble HER-2/neu ECD-Fc fusion protein (and not by rhCEA)
were conserved for higher scale production and purification.
Competitive ELISA was subsequently performed by inhibiting
antigen binding to Ab1 using the selected scFv fragments. This
strategy allowed us to isolate three fragments, termed scFv 39, 40
and 69, which recognised the binding site of Ab1 but exhibited
different random loops of five or six amino acids in the CDR3 of
the VH and VL domains. The analysis of these sequences showed
that random loops appended in H-CDR3 (the largest and most
diverse loop of the antigen recognition site of the antibody) for
anti-Id scFv 40 and 69 presented 5/6 identical amino acids,
whereas the H-CDR3 of anti-Id scFv 39 was quite different in
sequence and appeared to be more positively charged. Concerning
the L-CDR3, the three scFv used the DPL-16 germline gene
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Figure 7 Analysis of the binding of mouse sera to cells after the two immunisation schedules: protocol 1 with soluble anti-Id scFv 40 and 69 and protocol
2 with phage-displayed scFv. The binding experiments were performed either on (A) CHO cells which do not express the HER2/neu receptor or (B) SK-
OV-3-cells overexpressing HER2/neu receptor. The binding of antibodies was detected by FACS analysis using an FITC-labelled goat anti-mouse antibody.
All antibody binding experiments were performed in comparison with trastuzumab detected using a FITC-labelled anti-human antibody and with the
background fluorescence determined by binding on cells of the FITC-labelled secondary antibody alone. Curves indicate background fluorescence (solid
line), control mAb trastuzumab ( ), sera from mice immunised with PBS ( ), sera from mice immunised with anti-Id scFv 40 ( ), sera from mice immunised
with anti-Id scFv 69 (K), and sera from mice immunised with HER-2/neu ECD-Fc ( ).
HER-2/neu mimicry by human anti-idiotypic scFv
M Coelho et al
2038
British Journal of Cancer (2004) 90(10), 2032–2041 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
ssegment, L-CDR3 of anti-Id scFv 39 differed from the others,
especially from scFv 40, by a global positive charge. The L-CDR3 of
scFv 69 seemed to be very highly constrained by the three proline
residues in the loop.
As previously stated, two inhibition formats were used to
demonstrate that the selected scFv could be true Ab2b. In the first
one, HER-2/neu ECD-Fc completely inhibited the binding of
purified soluble scFv 40 and 69 on trastuzumab. Owing to the
partial inhibition observed for scFv 39, this fragment was not
considered for subsequent experiments. When the ELISA was
performed by inhibiting the binding of HER-2/neu antigen on
trastuzumab using Ab2 scFv 40 or Ab2 scFv 69 as inhibitors, an
inhibition of about 40% was observed. In this test, soluble
scFv was used at concentrations up to 250mgml
 1 (giving an
A490nm ranging from 1 to 1.5 by ELISA), that is, 10mM,
corresponding to a 1000-fold molar excess as compared with the
soluble HER-2/neu ECD-Fc fusion antigen. This suggests that the
lower inhibition observed in the second format (40 vs 90% in the
first one) could not be attributed to the low inhibitor concentra-
tion. Most likely, the difference between the affinity constants for
trastuzumab of anti-Id scFv 40 and 69 (in the mM range) and that of
HER-2/neu ECD-Fc fusion protein (in the nM range) could explain
this result. By SPR technology, an 83% inhibition of the binding of
the antigen on Ab1 by anti-Id scFv 69 was observed. This
technology allowed us to vizualise the real-time kinetics of the
reaction. Under these conditions, the dissociation of soluble scFv
from immobilised trastuzumab was minimal, in contrast with the
ELISA protocol where the incubation and washing steps could lead
to dissociation due to the relatively low affinity of the scFv for
trastuzumab. Furthermore, the percent inhibition determined by
BIACORE was calculated by subtracting the dissociation level of
soluble scFv from the association level of HER-2/neu ECD-Fc
fusion protein.
At this stage of the study, anti-Id scFv 40 and 69 were
predicted to be internal images of the tumour antigen HER-2/
neu and supposed to induce polyclonal anti-anti-Id antibodies
(Ab3) when injected into animals. Our vaccine strategy used anti-
Id scFv 40 and 69 as immunogens either in a purified soluble form
(protocol 1) or displayed on phage particles (protocol 2)
and administrated by different routes. Based on the work of
Galfre et al (1996), who obtained a strong antibody response in
mice when phages were injected in physiological saline but
found that the use of adjuvants resulted in higher titres especially
for poorly immunogenic epitopes, we used Freund’s adjuvants
in both our protocols. At the end of the immunisation schedules,
all the mice had developed an Ab3 response to the injected
anti-Id scFv, as shown by the results of inhibition ELISA for
the mice immunised with anti-Id scFv 69 (Figure 5). Among the
Ab3 antibodies, the Ab10 response is the only one clinically
relevant since it is the only one to bind the target (Bhattacharya-
Chatterjee et al, 1991). We indeed demonstrated an Ab10 response
by testing the immunoreactivity of each serum on HER-2/neu
ECD-Fc fusion protein. A similar anti-HER-2/neu ECD-Fc fusion
protein response was obtained in all immunised animals (with
slight differences in titres within each group) after three or four
immunisations with either 50mg purified anti-Id scFv 40 or anti-Id
scFv 69 (protocol 1) or about 1mg anti-Id scFv 40 or anti-Id scFv 69
exhibited on phages (protocol 2). These results are in agreement
with the findings of Galfre et al (1996), who showed an increased
immunogenicity by using phages as ‘carriers’ throughout the
immunisation schedule. No significant Ab10 reactivity was detected
in the sera of the negative control group injected with PBS. The
Ab10 nature of the induced antibodies was also studied by FACS
analysis of the mouse sera. This technology revealed that Ab1
(trastuzumab) and Ab3 sera bound significantly to HER-2/neu-
positive SK-OV-3 cells and confirmed the generation of true
anti-anti-Id as well as HER-2/neu-specific antibodies using either
soluble scFv or scFv displayed on phage particles (Figure 7).
As expected, in the positive control group of mice injected
with HER-2/neu ECD-Fc fusion protein, the observed immune
anti-HER-2/neu response was higher than in the group
injected with anti-Id scFv 40 and 69. It is important to remark
that (i) this response would probably be much lower in humans
since the extracellular domain of HER-2/neu is shed, circulates in
the sera of patients and is available to the immune system for
tolerance induction (Leitzel et al, 1992), (ii) the human Fc of the
fusion protein is immunogenic in mice but not in humans and (iii)
the immunogenicity of anti-Id scFv fragments could be increased
by incorporating additional immunogenic sequences such as
keyhole limpet haemocyanin (KLH) (Tripathi et al, 1998). Our
results with regard to immunisation using anti-Id scFv, either in
soluble form or displayed on phage, are in agreement with those of
Magliani et al (1998) who described the use of anti-Id scFv
antibody (soluble or phage-fused) to mimick the antigenic
properties of the type III capsular polysaccharide of group B
Streptococcus. As they did, we analysed the levels and types of
antibodies raised in mice throughout the two immunisation
schedules (data not shown). For immunisation protocol 1, the
calculated mean values (in arbitrary units, see Sect. 4.5) for the
levels of IgM, IgG and total Ig were at maximum 650, 250 and 530,
respectively, as compared with 650, 300 and 700 in the work of
Magliani et al (1998). Our results are thus similar and comparable
to theirs.
Our data indicate that the 30-kDa human anti-Id scFv
40 and 69 can induce an effective anti-HER-2/neu
humoral response in experimental animals and can serve as a
surrogate for the tumour antigen HER-2/neu. As future prospects
for our work, an active immunisation with anti-Id scFv 40
and 69 to prevent the development of tumours in a transgenic
mouse model of HER-2/neu mammary tumorigenesis (as a
model of human breast cancer) will be performed. This study will
also permit us to further analyse induced T-cell specific
antitumour responses as well as antibody-dependent cellular
cytotoxicity. In experimental tumour models, anti-Id mimicking
TAA were shown years ago to induce both B- and T-cell specific
antitumour immune responses (Dunn et al, 1987; Nelson et al,
1987). Recently, Baral et al (2001) reported the use of a murine
monoclonal anti-Id antibody as a surrogate antigen for human
HER-2/neu. They demonstrated that the anti-anti-Id (Ab3)
response generated against Ab2 in sera of immunised rabbits
could serve an important secondary effector function by enhancing
antitumour ADCC.
The human anti-Id scFv 40 and 69 should be useful tools to
delineate the role of individual immune HER-2/neu specific
antitumour responses and ultimately to develop strategies of
human anti-Id-based vaccines for enhancing such immunity in
patients bearing HER-2/neu-positive tumours.
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